Cedazuridine (E7727) (Compound 7a) hydrochloride can be used for researching of cancer that is an orally active inhibitor of cytidine deaminase (CDA) (IC 50 = 0.4 μM) [1].

Cedazuridine (Compound 7a) exhibits superior acid stability [1]. Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA ( 5-Azacytidine) in growth inhibition of AML cell lines [2].

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models [2]. Animal Model: Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models [2] Dosage: 3 mg/kg Administration: Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days Result: Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model. Animal Model: NSGS male mice [2] Dosage: 1, 3, 10 and 30 mg/kg Administration: Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies) Result: Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.